WO1993010783A2 - Quinolone derivatives and their use as ampa and nmda receptor antagonists - Google Patents
Quinolone derivatives and their use as ampa and nmda receptor antagonists Download PDFInfo
- Publication number
- WO1993010783A2 WO1993010783A2 PCT/GB1992/002182 GB9202182W WO9310783A2 WO 1993010783 A2 WO1993010783 A2 WO 1993010783A2 GB 9202182 W GB9202182 W GB 9202182W WO 9310783 A2 WO9310783 A2 WO 9310783A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- formula
- compound
- carboxy
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
Definitions
- This invention relates to a particular class of 2(lH)-quinolone derivatives which are selective non- competitive antagonists of N-methyl-D-aspartate (NMDA) receptors.
- the class of compounds provided by the present invention are ligands for the strychnine-insensitive glycine modulatory site of the NMDA receptor and are therefore useful in the treatment and/or prevention of neurodegenerative disorders arising as a consequence of such pathological conditions as stroke, hypoglycaemia, cerebral palsy, transient cerebral ischaemic attack, cerebral ischaemia during cardiac pulmonary surgery or cardiac arrest, perinatal asphyxia, epilepsy, Huntington's chorea, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Parkinson's disease, Olivo-ponto-cerebellar atrophy, anoxia such as from drowning, spinal cord and head injury, and poisoning by exogenous and endogenous NMDA receptor agonists and neurotoxins, including environmental neurotoxins.
- the compounds according to the present invention are also useful as anticonvulsant and antiemetic agents, as well as being of value in the prevention or reduction of dependence on dependence- inducing agents such as narcotics.
- NMDA receptor antagonists have recently been shown to possess analgesic (see, for example, Dickenson and Aydar, Neuroscience Lett.. 1991, 121. 263; Murray et al. , Pain. 1991, 44. / 179; and Woolf and Thompson, Pain, 1991, 4., 293) and anxiolytic (see, for example, US-5145866; and Kehne et al.. Eur. J. Pharmacol.. 1991, 193. 283) effects, and the compounds of the present invention may accordingly be useful in the management of pain and anxiety.
- analgesic see, for example, Dickenson and Aydar, Neuroscience Lett.. 1991, 121. 263; Murray et al. , Pain. 1991, 44. / 179; and Woolf and Thompson, Pain, 1991, 4., 293
- anxiolytic see, for example, US-5145866; and Kehne et al.. Eur. J. Pharmacol.. 1991, 193. 283
- NMDA receptor complex Compounds possessing functional antagonist properties for the NMDA receptor complex are stated in WO-A-91/19493 to be effective in the treatment of mood disorders, including major depression, bipolar disorder, dysthymia and seasonal affective disorder (c . also Trullas and Skolnick, Eur. J. Pharmacol.. 1990, 185. 1) .
- the compounds of the present invention may consequently be of benefit in the treatment and/or prevention of such disorders.
- EP-A-0420806 which are stated to be selective NMDA antagonists, are alleged thereby to be of potential utility in the treatment of inter alia migraine.
- Excitatory amino acid receptor antagonists including inter alia antagonists of NMDA receptors, are alleged in EP-A-0432994 to be of use in suppressing ernesis. 5
- Recent reports in the literature have also suggested a link between the neurotoxicity of certain viruses and the deleterious effects of these viruses on an organism caused by the potentiation of neurotransmission via excitatory amino acid receptors.
- the compounds of the present invention may be effective in controlling the manifestations of neuroviral diseases such as measles, rabies, tetanus (cf. Bagetta et al.. Br. J. Pharmacol..).
- NMDA antagonists have, moreover, been shown to have an effect on the neuroendocrine system (see, for example, van den Pol et al.. Science. 1990, 250, 1276;
- isoxazolepropionic acid (AMPA) receptors also known as quisqualate receptors.
- AMPA isoxazolepropionic acid
- An excitatory amino acid projection from the prefrontal cortex to the nucleus accumbens (a particular region of the forebrain possessing dopamine-sensitive neurones) is well known to
- the present invention accordingly provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof or a prodrug thereof:
- R 1 is a group of part formula (i) or (ii) :
- U and V independently represent cyano, carboxy, -COR 6 , -CO2R 6 , -CO.SR 6 , -CONHOH or -CONHNH2, ' n is zero or 1, preferably zero;
- T represents cyano, carboxy, -COR 6 , -CO2R 6 , -CO.SR 6 , -CONHOH, -CONHNH 2 or a group of formula
- the broken circle represents two non-adjacent double bonds in any position in the five-membered ring
- W, X, Y and Z independently represent oxygen, sulphur, nitrogen or carbon, provided that no more than one of , X, Y and Z represents oxygen or sulphur and at least one of , X, Y and Z is other than carbon
- one of E, F and G represents nitrogen or carbon and the remainder represent carbon;
- a 1 , A 2 and A 3 represent one, two or three substituents not exceeding the maximum number permissible by the disposition of heteroatoms in the five- or six- membered ring, which substituents are independently selected from hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -0R a , -SR a , -SOR a , -S0 2 R a , -S0 2 NR a R b , -NR a R b , -NR a COR b , -NR a C0 2 R, -COR a , -C ⁇ 2 a or -C0NR a R b ; or A 1 and A 2 or A 2 and A 3 together represent the residue of an aromatic or heteroaromatic ring; one of R 2 , R 3 , R 4 and R 5 represents hydrocarbon, a heterocyclic group, halogen, cyano, trifluoro
- R 6 represents hydrocarbon or a heterocyclic group
- R a and R b independently represent hydrogen, hydrocarbon or a heterocyclic group; for the manufacture of a medicament for the treatment and/or prevention of conditions, in particular neurodegenerative disorders, which require the administration of a selective non-competitive antagonist of NMDA receptors.
- the present invention further provides the use of a compound of formula I as defined above or a pharmaceutically acceptable salt thereof or a prodrug thereof for the manufacture of a medicament for the treatment and/or prevention of conditions, such as schizophrenia, which require the administration of an antagonist of AMPA receptors.
- the compounds of formula I can exist as alternative tautomeric forms. It is to be understood that all tautomeric forms of the compounds of formula I, as well as all possible mixtures thereof, are included within the scope of the present invention.
- hydrocarbon as used herein includes straight-chained, branched and cyclic groups containing up to 18 carbon atoms, suitably up to 15 carbon atoms, and conveniently up to 12 carbon atoms.
- Suitable hydrocarbon groups include C1-6 alkyl, C2- alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl(C1-6)alkyl, aryl, aryl(C 1 -6)alkyl, aryl(C 2 -6)alkenyl and aryl(C2-6)alkynyl.
- a heterocyclic group as used herein includes cyclic groups containing up to 18 carbon atoms and at least one heteroatom preferably selected from oxygen, nitrogen and sulphur.
- the heterocyclic group suitably contains up to 15 carbon atoms and conveniently up to 12 carbon atoms, and is preferably linked through carbon.
- suitable heterocyclic groups include C3-7 heterocycloalkyl, C3-7 heterocycloalkyl(C 1 -6)alkyl, heteroaryl and heteroaryl(C1-6)alkyl.
- Suitable alkyl groups include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl and butyl groups. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl.
- Suitable alkenyl groups include straight- chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples include vinyl and allyl groups.
- Suitable alkynyl groups include straight- chained and branched alkynyl groups containing.from 2 to 6 carbon atoms. Typical examples include ethynyl and propargyl groups.
- Suitable cycloalkyl groups include groups containing from 3 to 7 carbon atoms. Particular cycloalkyl groups are cyclopropyl and cyclohexyl. Suitable aryl groups include phenyl and naphthyl groups.
- Particular aryl(Ci- 6 )alkyl groups include benzyl, phenethyl, phenylpropyl and phenylbutyl.
- a particular aryl(C2-6)alkenyl group is phenylallyl.
- a particular aryl(C2-6)alkynyl group is phenylpropargyl.
- Suitable heterocycloalkyl groups include piperidyl, piperazinyl and morpholinyl groups.
- Suitable heteroaryl groups include pyridyl, quinolyl, isoquinolyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, furyl, benzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, imidazolyl, oxadiazolyl and thiadiazolyl groups.
- Particular heteroaryl groups are pyridyl, furyl, benzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl and oxadiazolyl.
- heteroaryl(Ci-6)alkyl groups include indolylethyl, indolylpropyl and thienylethyl.
- the hydrocarbon and heterocyclic groups may in turn be optionally substituted by one or more groups selected from C ⁇ - alkyl, adamantyl, phenyl, halogen, C1- haloalkyl, trifluoromethyl, hydroxy, C1-6 alkoxy, C1-6 alkoxy(C ⁇ - 6 )alkoxy, aryloxy, keto, C 1 - 3 alkylenedioxy, nitro, cyano, carboxy, C 2 -6 alkoxycarbonyl, C 2 -6 alkoxycarbonyl(C ⁇ - )alkyl, C 2 -6 alkylcarbonyloxy, optionally substituted arylcarbonyloxy, C2-6 alkylcarbonyl, optionally substituted arylcarbonyl, C 1 -6 alkylthio, C 1 -6 alkylsulphin
- halogen as used herein includes fluorine, chlorine, bromine and iodine, especially chlorine.
- R in the compounds of formula I above represents a group of formula - - ⁇ -e
- ⁇ represents a straight or branched alkylene chain containing from 1 to 6 carbon atoms
- this alkylene chain may be, for example, methylene, ethylene, 1-methylethylene, propylene or 2- methylpropylene, preferably methylene, ethylene or propylene.
- substituents represented by the group R include hydrogen, carboxy(C1-6)alkoxy, C2-6 alkoxycarbonyl(C ⁇ -6)alkoxy, C3-10 alkenyloxy, amino, phenyl(Ci- 6 )alkylamino, amino(C1 - ⁇ )alkylamino, di(C ⁇ - 6 )alkylamino(C ⁇ - 6 )alkylamino, carboxy(C 1 - 6 )alkylamino, C 2 -6 alkanoylamino, carboxy-carbonylamino, C2-6 alkoxycarbonyl-carbonylamino, carboxymethyl- carbonylamino, C 2 .6 alkoxycarbonylmethyl-carbonylamino, C 1 - 6 alkylsulphonylamino, phenylsulphonylamino, carboxy, C2-6 alkoxycarbonyl, carboxy(C ⁇ -6)ally1 and C2-6 alkoxycarbonyl(C1-6)
- substituent R include hydrogen, carboxy-methoxy, methoxycarbonyl- methoxy, allyloxy, amino, benzylamino, dimethylamino- ethylamino, dimethylamino-propylamino, acetylamino, carboxymethyl-carbonylamino, carboxy-carbonylamino, methoxycarbonyl-carbonylamino, methylsulphonylamino, phenylsulphonylamino, carboxy, methoxycarbonyl, carboxy ethyl and ethoxycarbonyl-methyl, especially hydrogen and amino.
- the five-membered heteroaromatic ring containing the ring atoms W to Z may be, for example, a furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, oxadiazole, thiadiazole, triazole or tetrazole ring, in particular a furan, thiophene, pyrrole, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1,2,4- thiadiazole, 1,3,4-thiadiazole or tetrazole ring.
- the ring is a furan, thiophene, pyrrole, 1,2,4-oxadiazole, 1,2,4-thiadiazole or tetrazole ring.
- the six-membered heteroaromatic ring containing the ring atoms E, F and G is a pyridine, pyrazine, pyrimidine or pyridazine ring, preferably pyridine or pyrazine.
- E, F and G each represents carbon.
- G represents nitrogen, and E and F each represents carbon.
- the number of substituents A 1 , A 2 and/or A 3 present on the five- or six-membered heteroaromatic ring containing the ring atoms W to Z or E to G respectively is one, two or three depending upon the disposition of heteroatoms in the heteroaromatic ring concerned.
- the five-membered heteroaromatic ring is an oxadiazole, thiadiazole or tetrazole ring
- only one substituent will be permitted; where, for example, the five-membered heteroaromatic ring is an oxazole or thiazole ring, one or two substituents will be permitted; and where, for example, the five-membered heteroaromatic ring is a furan, thiophene or pyrrole ring, one, two or three substituents will be permitted.
- the heteroaromatic ring is a six-membered ring containing the ring atoms E, F and G it will be appreciated that one, two or three substituents A 1 , A 2 and/or A 3 will be permitted.
- Suitable values for the groups A 1 , A 2 and/or A 3 include hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl(C 1 -6)alkyl, optionally substituted aryl, optionally substituted aryl(C 1 -6)alkyl, halogen, cyano, trifluoromethyl, nitro, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylthio, C 2 -6 alkenylthio, -COR a or -NR a R b , in which R a and R b are as defined above.
- T U or V represents a group of formula
- R 6 suitably represents C1-6 alkyl, C 2 -6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl(C 1 -6)alkyl, aryl, aryl- (C ⁇ -6)alkyl, aryl(C 2 -6)alkenyl, aryl(C 2 -6)alkynyl, C3-7 heterocycloalkyl(C ⁇ - )alkyl, heteroaryl, heteroaryl-
- the benzo moiety of the 2(lH)-quinolone ring system shown in formula I above contains at least one non-hydrogen substituent.
- Particular substituents include halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, carboxy, C1-6 alkyl, C ⁇ -6 alkoxy, C1-6 alkylthio and C2- alkoxycarbonyl.
- R 5 represents hydrogen and R 2 , R 3 and R 4 independently represent hydrogen, halogen, nitro, amino or C 1 - alkyl, provided that at least one of R 2 , R 3 and R 4 is other than hydrogen.
- R 3 and R 5 each represents hydrogen and R 2 and R 4 independently represent hydrogen, nitro, amino, methyl or halogen, especially chlorine, provided that at least one of R 2 and R 4 is other than hydrogen.
- R 4 represents chlorine.
- R 2 and R 3 , R 3 and R 4 , R 4 and R 5 , A 1 and A 2 or A 2 and A 3 represent the residue of an aromatic or heteroaromatic ring, this is suitably an optionally substituted benzene, pyridine, thiophene, thiazole or thiadiazole ring.
- substituents on the aromatic or heteroaromatic ring may be mentioned nitro, and C1-6 alkoxy such as methoxy.
- the present invention provides a pharmaceutical composition comprising a compound of formula IA or a pharmaceutically acceptable salt thereof or a prodrug thereof:
- R 11 is a group of part formula (i) or (ii) :
- U and V independently represent cyano, carboxy, -COR 6 , -C0 2 R 6 , -CO.SR 6 , -CONHOH or -C0NHNH 2 ; n is zero or 1, preferably zero; T represents cyano, carboxy, -COR 6 , -CO 2 R 6 , -CO.SR 6 , -CONHOH, -CONHNH 2 or a group of formula
- W, X, Y and Z independently represent oxygen, sulphur, nitrogen or carbon, provided that no more than one of W, X, Y and Z represents oxygen or sulphur and at least one of W, X, Y and Z is other than carbon; one of E, F and G represents nitrogen or carbon and the remainder represent carbon; A 1 , A 2 and A 3 represent one, two or three substituents not exceeding the maximum number permissible by the disposition of heteroatoms in the five- or six- membered ring, which substituents are independently selected from hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR a , -SR a , -SOR a , -S0 2 R a , -S0 2 NR a R b , -NR a R b , -NR a C0R b , -NR a C0 2 R b , -C0R a ,
- R 6 represents hydrocarbon or a heterocyclic group
- R a and R b independently represent hydrogen, hydrocarbon or a heterocyclic group; provided that, when R 11 represents carboxy or
- R 10 does not represent amino or C 1 -6 alkylamino; provided also that, when R 10 represents hydrogen, one of R 12 to R 15 represents methylthio or methylsulphonyl or one or two of R 12 to R 15 represent C 1 - 4 alkyl, C 1 - 4 alkoxy or halogen, and the remainder of the substituents R 12 to R 15 represent hydrogen, then R 11 does not represent a lH-tetrazol-5-yl group; in association with one or more pharmaceutically acceptable carriers and/or excipients.
- the invention also provides a compound of formula IA as defined above or a pharmaceutically acceptable salt thereof or a prodrug thereof for use in therapy.
- the substituents R 10 and R 11 to R 15 in the compounds of formula IA correspond to the substituents R and R 1 to R 5 respectively as defined with reference to the compounds of formula I.
- R 21 is a group of part formula (i) or (ii) :
- U and V independently represent cyano, carboxy, -COR 6 , -C0 2 R 6 , -CO.SR 6 , -CONHOH or -CONHNH 2 ; n is zero or 1, preferably zero; T represents cyano, carboxy, -COR 6 , -CO2R 6 , -CO.SR 6 , -CONHOH, -C0NHNH 2 or a group of formula
- the broken circle represents two non-adjacent double bonds in any position in the five-membered ring
- W, X, Y and Z independently represent oxygen, sulphur, nitrogen or carbon, provided that no more than one of W, X, Y and Z represents oxygen or sulphur and at least one of W, X, Y and Z is other than carbon
- one of E, F and G represents nitrogen or carbon and the remainder represent carbon;
- a 1 , A 2 and A 3 represent one, two or three substituents not exceeding the maximum number permissible by the disposition of heteroatoms in the five- or six- membered ring, which substituents are independently selected from hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR a , -SR a , -SOR a , -S0 2 R a , -S0 2 NR a R b , -NR a R b , -NR a COR b , -NR a C0 2 R b , -COR a , -C0 2 R 8 or -CONR a R ; or A 1 and A 2 or A 2 and A 3 together represent the residue of an aromatic or heteroaromatic ring; one of R 22 , R 23 , R 24 and R 25 represents hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl
- R 22 , R 23 , R 24 and R 25 independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR a , -SR a , -SOR a , -S0 2 R a , -S0 2 NR a R b , -NR a R , -NR a COR b , -NR a C0 2 R b , -COR a , -C0 2 R a or -C0NR a R b ; or R 22 and R 23 , R 23 and R 24 or R 24 and R 25 together represent the residue
- R 6 represents hydrocarbon or a heterocyclic group
- R a and R b independently represent hydrogen, hydrocarbon or a heterocyclic group; provided that, when R 21 represents carboxy or C 2 -7 alkoxycarbonyl, one of the substituents R 22 to R 25 represents chloro or bromo and the other three substituents R 22 to R 25 are hydrogen, then R 20 does not represent amino or C 1 -6 alkylamino; provided also that, when R 20 represents hydrogen, one of R 22 to R 25 represents methylthio or methyIsulphonyl or one or two of R 22 to R 25 represent C1-4 alkyl, C 1 - 4 alkoxy or halogen, and the remainder of the substituents R 22 to R 25 represent hydrogen, then R 21 does not represent a lH-tetrazol-5-yl group; provided further that, when R 21 is ethoxycarbonyl, R 23 is nitro and R 22 , R 24 and R 25 each represents hydrogen, then R 21 does not represent amino.
- the substituents R 20 and R 21 to R 25 in the compounds of formula IB correspond to the substituents R and R 1 to R 5 respectively as defined with reference to the compounds of formula I.
- R 21 include cyano, carboxy, cyclopropylcarbonyl, benzylcarbonyl, thienylvinylcarbonyl, methoxycarbonyl, ethoxycarbonyl, phenylthio-ethoxycarbonyl, propoxycarbonyl, allyloxycarbonyl, hydroxyphenyl-ethoxycarbonyl, bis(methoxymethoxy)phenyl-ethoxycarbonyl, (t-butoxycarbonylaminomethyl)phenyl-ethoxycarbonyl, hydroxyphenyl-propoxycarbonyl, hydroxyphenyl- butoxycarbonyl, methoxyphenyl-propenyloxycarbonyl, hydroxyphenyl-propynyloxycarbonyl, methoxyphenyl- propynyloxycarbonyl, thienyl-ethoxycarbonyl, indolyl- ethoxycarbonyl, methoxyindolyl-ethoxycarbon
- the salts of the compounds of formula IB will be non-toxic pharmaceutically acceptable salts.
- Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts.
- Suitable pharmaceutically acceptable salts of the compounds of formulae I, IA and IB above include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.
- acid addition salts may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- the present invention includes within its scope prodrugs of the compounds of formulae I, IA and IB above.
- prodrugs will be functional derivatives of the compounds of formulae I, IA and IB which are readily convertible in vivo into the required compound.
- R 31 represents carboxy, -COR 36 or -CO 2 R 36 ;
- R 32 represents hydrogen, halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, carboxy, C 1 -6 alkyl, C2-6 alkenyl, C 1 -6 alkoxy, C 1 -6 alkylthio or C 2 -6 alkoxycarbonyl;
- R 33 represents hydrogen or halogen
- R 34 represents halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, carboxy, C1- alkyl, C2-6 alkenyl, C ⁇ -6 alkoxy, C 1 -6 alkylthio or C 2 -6 alkoxycarbonyl;
- R3 represents C ⁇ - 6 alkyl, C 3 - 7 cycloalkyl, 5 aryl(C1-6)alkyl, aryl(C2-6)alkenyl, aryl(C2-6)alkynyl, heteroaryl(C1- )alkyl or heteroaryl(C2-6)alkenyl, any of which groups may be optionally substituted.
- substituent R 30 with reference to formula IIA above include hydrogen, carboxy, 10 carboxymethyl , methoxycarbonyl-methyl, carboxymethoxy, methoxycarbonyl-methoxy , dimethylamino-ethylamino , dimethylamino-propylamino, carboxymethyl-carbonylamino, carboxy-carbonylamino and methoxycarbonyl-carbonylamino.
- optional subtituents on the group 15 R 36 suitably include hydroxy, C 1 -6 alkoxy, C 1 - alkoxy(C1-6)alkoxy and C2-6 alkoxycarbonylamino(C1-6)alkyl, especially hydroxy, methoxy, methoxymethoxy and t- butoxycarbonylaminomethyl.
- R 36 with respect to formula 20 IIA include methyl, ethyl, n-propyl, cyclopropyl, benzyl, phenethyl, hydroxyphenethyl, bis(methoxymethoxy)- phenethyl, (t-butoxycarbonylaminomethyl)-phenethyl, phenylpropyl, hydroxyphenylpropyl, phenylbutyl, hydroxyphenylbutyl, phenylallyl, methoxyphenylallyl, 25.
- a preferred group R 36 is cyclopropyl.
- R 32 represents hydrogen, nitro, 30 methyl, ethyl, vinyl or halogen, especially chlorine or iodine.
- R 32 is hydrogen, ethyl or iodine.
- R 33 represents hydrogen or chlorine, preferably hydrogen.
- R 34 represents cyano, trifluoromethyl, nitro, methyl or halogen, preferably chlorine.
- a 11 represents C1-6 alkyl, C 2 -6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C 3 -7 cycloalkyl(C1-6)alkyl, aryl or aryl(C1-6)alkyl;
- R 42 represents hydrogen, halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, carboxy, C1-6 alkyl, C 2 -6 alkenyl, C1-6 alkoxy, C1-6 alkylthio or C 2 -6 alkoxycarbonyl;
- R 43 represents hydrogen or halogen
- R 44 represents halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, carboxy, C1-6 alkyl, C2-6 alkenyl, C1-6 alkoxy, C ⁇ -6 alkylthio or C2-6 alkoxycarbonyl.
- substituent R 40 with reference to formula IIB include hydrogen, amino, carboxy, carboxymethyl, methoxycarbonyl-methyl, carboxymethoxy, methoxycarbonyl-methoxy, allyloxy, benzylamino, dimethylamino-ethylamino, dimethylamino- propylamino, acetylamino, carboxymethyl-carbonylamino, carboxy-carbonylamino , methoxycarbonyl-carbonylamino , methylsulphonylamino and phenylsulphonylamino.
- suitable values for the group A 11 include methyl, ethyl, isopropyl, vinyl, allyl, cyclopropyl, cyclopropylmethyl, phenyl and benzyl.
- R 42 represents hydrogen, nitro, methyl, ethyl, vinyl or halogen, especially chlorine or iodine.
- R 42 is hydrogen, ethyl or iodine.
- R 43 represents hydrogen or chlorine, preferably hydrogen.
- R 44 represents cyano, trifluoromethyl, nitro, methyl or halogen, preferably chlorine.
- Specific compounds within the scope of the present invention include: 3-carboxy-7-chloro-2(1H)-quinolone; and salts and prodrugs thereof.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a "previously 5 undisclosed compound of formula I" as defined above or a pharmaceutically acceptable salt thereof or a prodrug thereof in association with one or more pharmaceutically acceptable carriers and/or excipients.
- the present invention further provides a 10 "previously undisclosed compound of formula I" or a pharmaceutically acceptable salt thereof or a prodrug thereof for use in therapy.
- compositions of this invention are preferably in unit dosage forms such as 15 tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, or suppositories, for oral, parenteral or rectal administration.
- the compositions may be presented in a form suitable for once-weekly or once-monthly 20 administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.
- the principal active ingredient is mixed with a 25. pharmaceutical carrier, e.g.
- a solid preformulation 30 composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof.
- preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
- This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention.
- the tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
- liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
- Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl- pyrrolidone or gelatin.
- a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day.
- the compounds may be administered on a regimen of 1 to 4 times per day. In a particular embodiment, the compounds may be conveniently administered by intravenous infusion.
- R 1 , R 2 , R 3 , R 4 and R 5 are as defined above; and V 1 represents an aldehyde (-CHO) or cyano (-CN) group, or a group of formula -CO-? a - ⁇ in which ⁇ a represents a straight or branched alkylene chain containing from 1 to 6 carbon atoms and e is as defined above.
- the reaction is conveniently carried out in the presence of a base, followed by a mild acidic work-up. Suitable bases of use in the reaction include sodium methoxide, sodium hydride and potassium hexamethyldisilazide.
- V 1 in the compounds of formula III above represents an aldehyde group
- the product of the reaction is a compound of formula I wherein R is hydrogen.
- V 1 represents a cyano group the product of the reaction is a compound of formula I wherein R is an amino group.
- V 1 represents a group of formula -CO- ⁇ a -e the product of the reaction is a compound of formula I wherein R is a group of formula -a- ⁇ -e in which ⁇ represents a chemical bond and ⁇ is a straight or branched alkylene group containing from 1 to 6 carbon atoms.
- R 1 , R 2 , R 3 , R 4 , R 5 and R a are as defined above; in the presence of a strong base, e.g. sodium methoxide; followed by quenching with a selenyl halide reagent, e.g. phenylselenyl chloride; and subsequent elimination of selenium to afford the double bond in the 3,4-position.
- a strong base e.g. sodium methoxide
- a selenyl halide reagent e.g. phenylselenyl chloride
- the reaction is conveniently effected in dichloromethane at room temperature or in 1,2- dichloroethane at reflux temperature, advantageously in the presence of a mild organic base such as triethylamine -and/or 4-dimethylaminopyridine.
- Suitable values for the reactive carboxylate moiety Q 1 include esters, for example C 1 - 4 alkyl esters; acid anhydrides, for example mixed anhydrides with C 1 - 4 alkanoic acids; acid halides, for example acid chlorides; orthoesters; and primary, secondary and tertiary amides.
- the group Q 1 is an acid halide group, in particular an acid chloride group.
- An alternative preferred species of formula Q 1 -CH2-R 1 is the activated ester derivative formed upon reaction of the carboxy compound HO2C-CH2-R 1 with bis(2-oxo-3- oxazolidinyl)phosphinic chloride (B0P-C1) .
- the compounds of formula I wherein R represents a carboxy group including the novel compounds according to the invention, may be prepared by a process which comprises reacting a compound of formula HO2C-CH2-R 1 with a compound of formula V:
- reaction is conveniently carried out in the presence of sodium acetate at an elevated temperature, e.g. 200 to 230°C, by analogy with the methodology described, for example, in J. Heterocycl. Chem.. 1989,
- ⁇ 10 represents an -NH- group
- a preferred base depending upon the nature of the reagent L- ⁇ -e, is sodium hydride or potassium hexamethyldisilazide, and the reaction is advantageously effected in a compatible solvent, such as tetrahydrofuran.
- the compounds of formula I wherein R represents a group of formula -a- ⁇ -e in which ⁇ represents an -NH- group, including the novel compounds according to the invention may be prepared by reacting a compound of formula f ⁇ N-jS-e, wherein ⁇ and e are as defined above, with a compound of formula VI above wherein ⁇ 10 represents an oxygen atom.
- reaction is conveniently effected by heating the reagents together at the reflux temperature of the mixture, by analogy with the methodology described, for example, in Vestn. Slov. Kern. Drus.. 1986, 33. 271; or, if necessary, by maintaining the reaction mixture at an elevated temperature for several days in a sealed tube.
- a given intermediate of formula VI above wherein ⁇ 10 represents sulphur may be prepared from the corresponding compound of formula VI wherein ⁇ 10 represents oxygen by treating the latter compound firstly with N,N-dimethylthiocarbamyl chloride and then with a mineral acid such as hydrochloric acid, followed by hydrolysis with base, e.g. sodium hydroxide, by analogy with the procedure described in WO-A-91/01973.
- the intermediates of formula VI above wherein ⁇ 10 represents oxygen may be prepared by the procedures described in EP-A-0459561 or by methods analogous thereto. Additional sources of reference for preparing compounds corresponding to those of formula VI above wherein ⁇ 10 represents oxygen include, for example, J. Or ⁇ . Chem.. 1976, 4JL, 825.
- the aromatic intermediates of formulae IV and V above, as well as the intermediates of formula HO 2 C-CH 2 -R 1 and Q 1 -CH2-R 1 where they are not commercially available, may be prepared by the methods described in the accompanying Examples, or by methods analogous thereto which will be readily apparent to those skilled in the art.
- the compounds of formula VI above wherein ⁇ 10 represents an -NH- group which can be used as intermediates in the preparation of compounds in accordance with the present invention, are themselves compounds according to the invention. It is to be understood that any compound of formula I, IA or IB initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further desired compound of formula I, IA or IB respectively using techniques known from the art.
- a compound of formula I initially obtained wherein R is carboxy may be converted into a corresponding compound of formula I wherein R represents a O ⁇ - 6 alkoxycarbonyl group by standard esterification procedures common in the art.
- a compound of formula I initially obtained wherein R 1 represents a group of formula -CO2R 6 may subsequently be converted into the desired compound of formula I wherein R 1 represents a different group -CO 2 R 6 by conventional transesterification procedures known from the art.
- this transesterification can be brought about simply by heating the ester of formula I initially obtained, at a temperature in excess of 130°C, in an alcohol of formula Rt ⁇ H in which R 6 represents the residue of the ester group -CO 2 R 6 in the desired final product of formula I, the alcohol R ⁇ H itself simultaneously serving as solvent.
- the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.
- the compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di- p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-1- tartaric acid followed by fractional crystallization and regeneration of the free base.
- the compounds may also be resolved by formation of diastereomeric esters or amides. followed by chromatographic separation and removal of the chiral auxiliary.
- any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wutts, Protective Groups in Organic Synthesis. John Wiley & Sons, 1991.
- the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
- the following Examples illustrate the preparation of compounds according to the invention.
- the compounds useful in this invention potently and selectively block responses to NMDA and/or AMPA in a brain slice from rat cortex, and inhibit the binding of agonists and antagonists to the strychnine-insensitive site present on the NMDA receptor and/or AMPA binding to rat forebrain membranes.
- test compounds to displace 3 H- L-689,560 (trans-2-carboxy-5,7-dichloro-4-phenyl- aminocarbonylamino-1,2,3,4-tetrahydroquinoline) binding to the strychnine-insensitive glycine site present on the NMDA receptor of rat forebrain membranes was determined by the method of Grimwood et al. , Proceedings of The British Pharmacological Society. July 1991, Abstract C78. The concentration of the compounds of the accompanying Examples required to displace 50% of the specific binding (IC50) is below 50 ⁇ M in each case.
- the amide was dissolved in DMF (20ml) and treated with sodium hydride (0.492g, 80% disp. in oil). The reaction was heated at 100°C for 3.5 h, cooled and poured into water (100ml). The reaction was acidified to pHl (IN HCl), and a solid was collected by filtration to give the title compound, 87mg (mp > 330°C (DMF-water)).
- Tablet Preparation Tablets containing 1.0, 2.0, 25.0, 26.0, 50.0 and lOO.Omg, respectively of the following compounds are prepared as illustrated below:
- All of the active compound, cellulose, and a portion of the corn starch are mixed and granulated to 10% corn starch paste.
- the resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate.
- the resulting granulation is then compressed into tablets containing l.Omg, 2.0mg, 25.0mg, 26.0mg, 50.0mg and lOOmg of the active ingredient per tablet.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4511514A JPH07501313A (en) | 1991-11-29 | 1992-11-25 | quinolone derivatives |
EP92924762A EP0614363A1 (en) | 1991-11-29 | 1992-11-25 | Quinolone derivatives |
US08/244,310 US5475008A (en) | 1991-11-29 | 1992-11-25 | Quinolone derivatives |
CA002122841A CA2122841A1 (en) | 1991-11-29 | 1992-11-25 | Quinolone derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9125485.4 | 1991-11-29 | ||
GB919125485A GB9125485D0 (en) | 1991-11-29 | 1991-11-29 | Therapeutic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1993010783A2 true WO1993010783A2 (en) | 1993-06-10 |
WO1993010783A3 WO1993010783A3 (en) | 1993-07-22 |
Family
ID=10705486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1992/002182 WO1993010783A2 (en) | 1991-11-29 | 1992-11-25 | Quinolone derivatives and their use as ampa and nmda receptor antagonists |
Country Status (6)
Country | Link |
---|---|
US (1) | US5475008A (en) |
EP (1) | EP0614363A1 (en) |
JP (1) | JPH07501313A (en) |
CA (1) | CA2122841A1 (en) |
GB (1) | GB9125485D0 (en) |
WO (1) | WO1993010783A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5633379A (en) * | 1994-06-02 | 1997-05-27 | Ciba-Geigy Corporation | 3-heteroaliphatyl- and 3-hetero(aryl)aliphatyl-2(1H)-quinolone derivatives |
WO1999000020A1 (en) * | 1997-06-27 | 1999-01-07 | Hoechst Schering Agrevo Gmbh | 3-(5-tetrazolyl carbonyl)-2-quinolones and products for protecting useful plants containing the same |
EP1020453A1 (en) * | 1997-09-01 | 2000-07-19 | Kyorin Pharmaceutical Co., Ltd. | 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid deri vatives, addition salts thereof, and processes for the preparation of both |
WO2000050416A1 (en) * | 1999-02-26 | 2000-08-31 | Kyorin Pharmaceutical Co., Ltd. | 6-substituted heteroquinolinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both |
US6147088A (en) * | 1996-05-20 | 2000-11-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
US6150352A (en) * | 1996-05-20 | 2000-11-21 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
US6150522A (en) * | 1996-05-20 | 2000-11-21 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
US6162813A (en) * | 1996-05-20 | 2000-12-19 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
US7307089B2 (en) | 2005-07-27 | 2007-12-11 | Roche Palo Alto Llc | Aryloxy quinolines and uses thereof |
US8299085B2 (en) | 2004-07-27 | 2012-10-30 | Novartis Ag | Quinazoline derivatives |
WO2012164085A1 (en) | 2011-06-03 | 2012-12-06 | Merz Pharma Gmbh & Co. Kgaa | Glycine b antagonists |
US8513268B2 (en) | 2005-04-11 | 2013-08-20 | Novartis Ag | 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy |
US9834544B2 (en) | 2010-04-02 | 2017-12-05 | Senomyx, Inc. | Sweet flavor modifier |
US9902737B2 (en) | 2010-04-02 | 2018-02-27 | Senomyx, Inc. | Sweet flavor modifier |
US11339128B2 (en) | 2014-11-07 | 2022-05-24 | Firmenich Incorporated | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2184960T3 (en) * | 1996-05-15 | 2003-04-16 | Pfizer | NEW PYRIMIDIN-4-ONAS- (5,6) -HETEROARIL CONDENSED 2.3 DISPOSED. |
US6323208B1 (en) | 1997-09-05 | 2001-11-27 | Pfizer Inc | Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones |
IL125950A0 (en) * | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
US7214711B2 (en) * | 1998-12-23 | 2007-05-08 | Neurotherapeutics Pharma Llc | Method of treating migraine headache without aura |
US8008283B2 (en) * | 1998-12-23 | 2011-08-30 | Neurotherapeutics Pharma, Inc. | Methods and compositions for the treatment of neuropsychiatric disorders |
US8722668B2 (en) | 1998-12-23 | 2014-05-13 | Daryl W. Hochman | Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders |
US20060025387A1 (en) * | 1998-12-23 | 2006-02-02 | Cytoscan Sciences Llc | Compositions and methods for the treatment of disorders of the central and peripheral nervous systems |
US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
JP2009511629A (en) * | 2005-10-17 | 2009-03-19 | ニューロセラピューティクス ファーマ, インコーポレイテッド | Analogues of diuretic-like compounds useful in the regulation of central nervous system diseases |
TWI366565B (en) | 2007-06-06 | 2012-06-21 | Otsuka Pharma Co Ltd | Quinolone compound and pharmaceutical composition |
EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4284768A (en) * | 1980-07-02 | 1981-08-18 | American Home Products Corporation | 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives |
EP0120483A1 (en) * | 1983-03-25 | 1984-10-03 | Merrell Dow Pharmaceuticals Inc. | (1H-tetrazol-5-yl)-2(1H)-quinolinones |
EP0303387A1 (en) * | 1987-08-12 | 1989-02-15 | Merck Sharp & Dohme Ltd. | Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders |
US4902695A (en) * | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4208304A1 (en) * | 1992-03-16 | 1993-09-23 | Merck Patent Gmbh | 2-OXOCHINOLINDERIVATE |
-
1991
- 1991-11-29 GB GB919125485A patent/GB9125485D0/en active Pending
-
1992
- 1992-11-25 CA CA002122841A patent/CA2122841A1/en not_active Abandoned
- 1992-11-25 US US08/244,310 patent/US5475008A/en not_active Expired - Fee Related
- 1992-11-25 EP EP92924762A patent/EP0614363A1/en not_active Withdrawn
- 1992-11-25 WO PCT/GB1992/002182 patent/WO1993010783A2/en not_active Application Discontinuation
- 1992-11-25 JP JP4511514A patent/JPH07501313A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4284768A (en) * | 1980-07-02 | 1981-08-18 | American Home Products Corporation | 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives |
EP0120483A1 (en) * | 1983-03-25 | 1984-10-03 | Merrell Dow Pharmaceuticals Inc. | (1H-tetrazol-5-yl)-2(1H)-quinolinones |
EP0303387A1 (en) * | 1987-08-12 | 1989-02-15 | Merck Sharp & Dohme Ltd. | Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders |
US4902695A (en) * | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5633379A (en) * | 1994-06-02 | 1997-05-27 | Ciba-Geigy Corporation | 3-heteroaliphatyl- and 3-hetero(aryl)aliphatyl-2(1H)-quinolone derivatives |
US6150352A (en) * | 1996-05-20 | 2000-11-21 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
US6162813A (en) * | 1996-05-20 | 2000-12-19 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
US6150522A (en) * | 1996-05-20 | 2000-11-21 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
US6147088A (en) * | 1996-05-20 | 2000-11-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
WO1999000020A1 (en) * | 1997-06-27 | 1999-01-07 | Hoechst Schering Agrevo Gmbh | 3-(5-tetrazolyl carbonyl)-2-quinolones and products for protecting useful plants containing the same |
EP1020453A4 (en) * | 1997-09-01 | 2000-11-08 | Kyorin Seiyaku Kk | 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid deri vatives, addition salts thereof, and processes for the preparation of both |
EP1020453A1 (en) * | 1997-09-01 | 2000-07-19 | Kyorin Pharmaceutical Co., Ltd. | 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid deri vatives, addition salts thereof, and processes for the preparation of both |
WO2000050416A1 (en) * | 1999-02-26 | 2000-08-31 | Kyorin Pharmaceutical Co., Ltd. | 6-substituted heteroquinolinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both |
US6562839B1 (en) | 1999-02-26 | 2003-05-13 | Kyorin Pharmaceutical Co., Ltd. | 6-substituted heteroquinolinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both |
US8299085B2 (en) | 2004-07-27 | 2012-10-30 | Novartis Ag | Quinazoline derivatives |
US8513268B2 (en) | 2005-04-11 | 2013-08-20 | Novartis Ag | 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy |
US7307089B2 (en) | 2005-07-27 | 2007-12-11 | Roche Palo Alto Llc | Aryloxy quinolines and uses thereof |
US9834544B2 (en) | 2010-04-02 | 2017-12-05 | Senomyx, Inc. | Sweet flavor modifier |
US9902737B2 (en) | 2010-04-02 | 2018-02-27 | Senomyx, Inc. | Sweet flavor modifier |
WO2012164085A1 (en) | 2011-06-03 | 2012-12-06 | Merz Pharma Gmbh & Co. Kgaa | Glycine b antagonists |
US11339128B2 (en) | 2014-11-07 | 2022-05-24 | Firmenich Incorporated | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers |
Also Published As
Publication number | Publication date |
---|---|
US5475008A (en) | 1995-12-12 |
CA2122841A1 (en) | 1993-06-10 |
JPH07501313A (en) | 1995-02-09 |
GB9125485D0 (en) | 1992-01-29 |
WO1993010783A3 (en) | 1993-07-22 |
EP0614363A1 (en) | 1994-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5475008A (en) | Quinolone derivatives | |
US5420155A (en) | Tetramic acid derivatives | |
US5252584A (en) | Hydroxyquinolone derivatives | |
JP6517928B2 (en) | Indolecarboxamides useful as kinase inhibitors | |
US5426106A (en) | Pyrrolo-pyridazinone derivatives | |
DE60115069T2 (en) | CHINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | |
WO1993011115A2 (en) | Quinolone derivatives and their use as nmda and ampa receptor antagonists | |
DE69426422T2 (en) | PYRIDAZINO-CHINOLINE COMPOUNDS | |
JP2018511647A (en) | Heterocyclic compounds as IDO inhibitors and TDO inhibitors | |
JPH07505407A (en) | indole derivative | |
EA028814B1 (en) | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES | |
JPH07138232A (en) | Benzoheterocyclic compound | |
WO2014131760A1 (en) | Trifluormethyl-substituted ring-fused pyrimidines and use thereof | |
JP2001505567A (en) | Novel substituted pyrazole derivatives for the treatment of cardiovascular diseases | |
JP2021512075A (en) | Inhibition of transient receptor potential A1 ion channels | |
EP3191452A1 (en) | Substituted n,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents | |
WO2011095057A1 (en) | Benzimidazole derivatives and pharmaceutical compositions and uses thereof | |
JPS58225065A (en) | 2-quinolone derivative | |
US5693640A (en) | Pyridazino-indole derivatives | |
US5580877A (en) | Pyrazolo-quinoline derivatives for treating cerebral ischemia | |
CN105026399B (en) | As the pyrrolo-triazine class compound of potassium channel inhibitors | |
US5376748A (en) | Nitroquinolone derivatives | |
GB2288800A (en) | Pyrazolo-quinoline derivatives as NMDA and AMPA antagonists | |
JPH03141257A (en) | Dihydropyridine derivative | |
JP2000344775A (en) | New compound and medicinal composition containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
CFP | Corrected version of a pamphlet front page |
Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2122841 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992924762 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08244310 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1992924762 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992924762 Country of ref document: EP |